<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font17 { font-size : 17; } .font18 { font-size : 18; } .font26 { font-size : 26; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">and </span>
   <span class="font26">the </span>
   <span class="font18">with </span>
   <span class="font17">resistance </span>
   <span class="font17">for </span>
   <span class="font15">was </span>
   <span class="font15">study </span>
   <span class="font15">al. </span>
   <span class="font14">treatment </span>
   <span class="font14">patients </span>
   <span class="font14">tuberculosis </span>
   <span class="font13">STRONG </span>
   <span class="font13">drug </span>
   <span class="font13">were </span>
   <span class="font13">[]. </span>
   <span class="font13">â€" </span>
   <span class="font13">malaria </span>
   <span class="font13">that </span>
   <span class="font13">from </span>
   <span class="font12">The </span>
   <span class="font12">HIV </span>
   <span class="font12">studies </span>
   <span class="font12">clinical </span>
   <span class="font12">outcomes </span>
   <span class="font12">cohort </span>
   <span class="font12">MDR-TB </span>
   <span class="font12">among </span>
   <span class="font12">costs </span>
   <span class="font12">failure </span>
   <span class="font12">drug-resistant </span>
   <span class="font12">due </span>
   <span class="font12">outcome </span>
   <span class="font12">resistant </span>
   <span class="font11">{background </span>
   <span class="font11">economic </span>
   <span class="font11">than </span>
   <span class="font11">Retrospective </span>
   <span class="font11">AMR </span>
   <span class="font11">public </span>
   <span class="font11">cases </span>
   <span class="font11">had </span>
   <span class="font11">compared </span>
   <span class="font11">margin </span>
   <span class="font11">per </span>
   <span class="font11">those </span>
   <span class="font11">Infect. </span>
   <span class="font11">{border-style </span>
   <span class="font11">(%) </span>
   <span class="font11">emergence </span>
   <span class="font11">strains </span>
   <span class="font11">are </span>
   <span class="font11">associated </span>
   <span class="font11">have </span>
   <span class="font11">model </span>
   <span class="font11">multidrug-resistant </span>
   <span class="font11">new </span>
   <span class="font11">px;} </span>
   <span class="font11">this </span>
   <span class="font11">#ffffff;} </span>
   <span class="font11">cost </span>
   <span class="font11">higher </span>
   <span class="font11">included </span>
   <span class="font11">increase </span>
   <span class="font11">patient </span>
   <span class="font11">risk </span>
   <span class="font11">transmission </span>
   <span class="font11">Med. </span>
   <span class="font11">health </span>
   <span class="font11">impacts </span>
   <span class="font11">malaria, </span>
   <span class="font11">mortality </span>
   <span class="font11">.%, </span>
   <span class="font11">USA </span>
   <span class="font11">chloroquine </span>
   <span class="font10">Health </span>
   <span class="font10">South </span>
   <span class="font10">artemisinin </span>
   <span class="font10">falciparum </span>
   <span class="font10">has </span>
   <span class="font10">health, </span>
   <span class="font10">not </span>
   <span class="font10">prevalence </span>
   <span class="font10">rates </span>
   <span class="font10">reported </span>
   <span class="font10">review </span>
   <span class="font10">three </span>
   <span class="font10">times </span>
   <span class="font10">MDR </span>
   <span class="font10">Prospective </span>
   <span class="font10">WEAK </span>
   <span class="font10">antiretroviral </span>
   <span class="font10">during </span>
   <span class="font10">evidence </span>
   <span class="font10">impact </span>
   <span class="font10">infectious </span>
   <span class="font10">million </span>
   <span class="font10">spread </span>
   <span class="font10">Tuberculosis </span>
   <span class="font10">adverse </span>
   <span class="font10">death </span>
   <span class="font10">found </span>
   <span class="font10">increased </span>
   <span class="font10">infection </span>
   <span class="font10">other </span>
   <span class="font10">resistance, </span>
   <span class="font10">these </span>
   <span class="font10">total </span>
   <span class="font10">.â€".) </span>
   <span class="font10">Africa </span>
   <span class="font10">Trop. </span>
   <span class="font10">after </span>
   <span class="font10">burden </span>
   <span class="font10">countries </span>
   <span class="font10">disease </span>
   <span class="font10">greater </span>
   <span class="font10">mean </span>
   <span class="font10">one </span>
   <span class="font10">respectively, </span>
   <span class="font10">significant </span>
   <span class="font10">therapy </span>
   <span class="font10">which </span>
   <span class="font10">HIV-infected </span>
   <span class="font10">Lung </span>
   <span class="font10">Mycobacterium </span>
   <span class="font10">Plasmodium </span>
   <span class="font10">Treatment </span>
   <span class="font10">Tuberc. </span>
   <span class="font10">been </span>
   <span class="font10">case </span>
   <span class="font10">confidence </span>
   <span class="font10">diseases </span>
   <span class="font10">drugs </span>
   <span class="font10">isoniazid </span>
   <span class="font10">large </span>
   <span class="font10">more </span>
   <span class="font10">prospective </span>
   <span class="font10">ratio </span>
   <span class="font10">showed </span>
   <span class="font10">where </span>
   <span class="font10">would </span>
   <span class="font10">.). </span>
   <span class="font10">... </span>
   <span class="font10">AIDS </span>
   <span class="font10">Malaria </span>
   <span class="font10">Resistance </span>
   <span class="font10">San </span>
   <span class="font10">Study </span>
   <span class="font10">XDR-TB </span>
   <span class="font10">averaged </span>
   <span class="font10">between </span>
   <span class="font10">deaths </span>
   <span class="font10">first-line </span>
   <span class="font10">high </span>
   <span class="font10">infections </span>
   <span class="font10">interval </span>
   <span class="font10">many </span>
   <span class="font10">significantly </span>
   <span class="font10">two </span>
   <span class="font10">use </span>
   <span class="font10">using </span>
   <span class="font10">&amp;lt; </span>
   <span class="font10">Cambodia </span>
   <span class="font10">Cross-sectional </span>
   <span class="font10">India, </span>
   <span class="font10">New </span>
   <span class="font10">Patients </span>
   <span class="font10">Public </span>
   <span class="font10">also </span>
   <span class="font10">antimicrobial </span>
   <span class="font10">average </span>
   <span class="font10">increasing </span>
   <span class="font10">infected </span>
   <span class="font10">levels </span>
   <span class="font10">multidrug </span>
   <span class="font10">only </span>
   <span class="font10">outbreak </span>
   <span class="font10">px; </span>
   <span class="font10">rate </span>
   <span class="font10">used </span>
   <span class="font10">virological </span>
   <span class="font10">{font-family </span>
   <span class="font10">(.â€".) </span>
   <span class="font10">AMR. </span>
   <span class="font10">DR-TB </span>
   <span class="font10">Table </span>
   <span class="font10">World </span>
   <span class="font10">additional </span>
   <span class="font10">articles </span>
   <span class="font10">diagnosis </span>
   <span class="font10">each </span>
   <span class="font10">estimated </span>
   <span class="font10">font-size </span>
   <span class="font10">initial </span>
   <span class="font10">injectable </span>
   <span class="font10">multiple </span>
   <span class="font10">over </span>
   <span class="font10">predicted </span>
   <span class="font10">remained </span>
   <span class="font10">resulted </span>
   <span class="font10">retrospective </span>
   <span class="font10">second-line </span>
   <span class="font10">there </span>
   <span class="font10">time </span>
   <span class="font10">versus </span>
   <span class="font10">will </span>
   <span class="font10">(adjusted </span>
   <span class="font10">Among </span>
   <span class="font10">China </span>
   <span class="font10">Cohort </span>
   <span class="font10">Dis. </span>
   <span class="font10">Dis../ </span>
   <span class="font10">Disease </span>
   <span class="font10">Francisco </span>
   <span class="font10">However, </span>
   <span class="font10">Outcome </span>
   <span class="font10">Philippines, </span>
   <span class="font10">Russia, </span>
   <span class="font10">This </span>
   <span class="font10">[,]. </span>
   <span class="font10">all </span>
   <span class="font10">caused </span>
   <span class="font10">children </span>
   <span class="font10">conducted </span>
   <span class="font10">decrease </span>
   <span class="font10">double; </span>
   <span class="font10">including </span>
   <span class="font10">its </span>
   <span class="font10">least </span>
   <span class="font10">likely </span>
   <span class="font10">outcomes, </span>
   <span class="font10">period </span>
   <span class="font10">poor </span>
   <span class="font10">potential </span>
   <span class="font10">proportion </span>
   <span class="font10">published </span>
   <span class="font10">regimen </span>
   <span class="font10">regimens </span>
   <span class="font10">results </span>
   <span class="font10">sensitive </span>
   <span class="font10">severe </span>
   <span class="font10">similar </span>
   <span class="font10">terms </span>
   <span class="font10">transmitted </span>
   <span class="font10">treated </span>
   <span class="font10">tuberculosis, </span>
   <span class="font10">without </span>
   <span class="font10">year </span>
   <span class="font10">Â·% </span>
   <span class="font10">(.%) </span>
   <span class="font10">(from </span>
   <span class="font10">.collab: </span>
   <span class="font10">.â€".; </span>
   <span class="font10">And </span>
   <span class="font10">Antimicrobial </span>
   <span class="font10">Author </span>
   <span class="font10">CDN </span>
   <span class="font10">Drug </span>
   <span class="font10">Hyg../ajtmh... </span>
   <span class="font10">Mexico </span>
   <span class="font10">ONEe./journal.pone. </span>
   <span class="font10">Saudi </span>
   <span class="font10">Soc. </span>
   <span class="font10">United </span>
   <span class="font10">address </span>
   <span class="font10">analysis </span>
   <span class="font10">annual </span>
   <span class="font10">antimalarial </span>
   <span class="font10">article </span>
   <span class="font10">association </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">but </span>
   <span class="font10">cases, </span>
   <span class="font10">combination </span>
   <span class="font10">could </span>
   <span class="font10">development </span>
   <span class="font10">different </span>
   <span class="font10">excess </span>
   <span class="font10">fluoroquinolones </span>
   <span class="font10">four </span>
   <span class="font10">global </span>
   <span class="font10">gonorrhea </span>
   <span class="font10">identified </span>
   <span class="font10">incidence </span>
   <span class="font10">incident </span>
   <span class="font10">inhibitors </span>
   <span class="font10">into </span>
   <span class="font10">leading </span>
   <span class="font10">may </span>
   <span class="font10">months </span>
   <span class="font10">most </span>
   <span class="font10">number </span>
   <span class="font10">outcomes. </span>
   <span class="font10">poorer </span>
   <span class="font10">research </span>
   <span class="font10">resistance. </span>
   <span class="font10">result </span>
   <span class="font10">reverse-transcriptase </span>
   <span class="font10">review. </span>
   <span class="font10">rifampicin </span>
   <span class="font10">search </span>
   <span class="font10">shorter </span>
   <span class="font10">solid; </span>
   <span class="font10">studies, </span>
   <span class="font10">sulfadoxine-pyrimethamine </span>
   <span class="font10">survival </span>
   <span class="font10">susceptible </span>
   <span class="font10">their </span>
   <span class="font10">threat </span>
   <span class="font10">viral </span>
   <span class="font10">who </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">(MDR-TB) </span>
   <span class="font10">(hazard </span>
   <span class="font10">.â€".). </span>
   <span class="font10">AND </span>
   <span class="font10">Artemisinin </span>
   <span class="font10">Assessment </span>
   <span class="font10">Control </span>
   <span class="font10">DS-TB </span>
   <span class="font10">During </span>
   <span class="font10">Economic </span>
   <span class="font10">GSS </span>
   <span class="font10">HIV. </span>
   <span class="font10">INH </span>
   <span class="font10">MODERATE </span>
   <span class="font10">Quality </span>
   <span class="font10">Research </span>
   <span class="font10">Southern </span>
   <span class="font10">Studies </span>
   <span class="font10">US$ </span>
   <span class="font10">WHO </span>
   <span class="font10">[MeSH </span>
   <span class="font10">active </span>
   <span class="font10">antimicrobials </span>
   <span class="font10">bold </span>
   <span class="font10">classes </span>
   <span class="font10">community </span>
   <span class="font10">courier; </span>
   <span class="font10">data </span>
   <span class="font10">death, </span>
   <span class="font10">death; </span>
   <span class="font10">defined </span>
   <span class="font10">effective </span>
   <span class="font10">efficacy </span>
   <span class="font10">either </span>
   <span class="font10">em; </span>
   <span class="font10">epidemic </span>
   <span class="font10">estimates </span>
   <span class="font10">fatality </span>
   <span class="font10">findings </span>
   <span class="font10">following </span>
   <span class="font10">gonococcal </span>
   <span class="font10">gonorrhea. </span>
   <span class="font10">healthcare </span>
   <span class="font10">ijerph---t_Table </span>
   <span class="font10">implications </span>
   <span class="font10">increase, </span>
   <span class="font10">individuals </span>
   <span class="font10">introduced </span>
   <span class="font10">isolates </span>
   <span class="font10">low </span>
   <span class="font10">major </span>
   <span class="font10">management </span>
   <span class="font10">maternal </span>
   <span class="font10">mathematical </span>
   <span class="font10">medical </span>
   <span class="font10">morbidity </span>
   <span class="font10">non-MDR </span>
   <span class="font10">non-MDR-TB </span>
   <span class="font10">observational </span>
   <span class="font10">observed </span>
   <span class="font10">organisms </span>
   <span class="font10">overall </span>
   <span class="font10">parasite </span>
   <span class="font10">particularly </span>
   <span class="font10">partner </span>
   <span class="font10">patient, </span>
   <span class="font10">percentage </span>
   <span class="font10">policy </span>
   <span class="font10">protease </span>
   <span class="font10">pt;} </span>
   <span class="font10">reaching </span>
   <span class="font10">reported. </span>
   <span class="font10">respectively </span>
   <span class="font10">response </span>
   <span class="font10">since </span>
   <span class="font10">strain </span>
   <span class="font10">subjects </span>
   <span class="font10">success </span>
   <span class="font10">surveillance </span>
   <span class="font10">survey </span>
   <span class="font10">therapies </span>
   <span class="font10">under </span>
   <span class="font10">virologic </span>
   <span class="font10">vs. </span>
   <span class="font10">western </span>
   <span class="font10">when </span>
   <span class="font10">while </span>
   <span class="font10">years </span>
  </p>
 </body>
</html>
